BRAF and Miyoshi myopathy: In order to gain further insights into the longitudinal status of BRAF/NRAS/KRAS mutations, we analyzed specimens taken from 19 patients at two different times: 14 with MM and two with pPCL at onset and relapse; two with MM at onset and at the time of leukemic transformation; and one at early and relapsed leukemic phase (Table 2 and Figure 4).